|
| Status |
Public on Jan 01, 2019 |
| Title |
The SUMO Pathway as a Therapeutic Option in Pancreatic Cancer |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
Pancreatic ductal adenocarcinoma (PDAC) still carries a dismal prognosis with overall five-year survival of 8%. Conventional combination chemotherapies are a clear advance in the treatment of PDAC, however subtypes of the disease exist, which exhibit extensive resistance to such therapies. Genomic MYC amplifications represent a distinct subset of PDAC with an aggressive tumor biology. It is clear that hyperactivation of MYC generates dependencies, which can be exploited therapeutically. To find MYC-associated dependency we analyzed human PDAC expression dataset. We observed that MYC is connected to the sumoylation machinery in PDAC. Components of the SUMO pathway mark a PDAC subtype with worse prognosis and we provide evidence that PDACs with a MYChigh/SUMOhigh phenotype respond to a novel SUMO inhibitor, offering the opportunity to develop novel stratified PDAC therapies
|
| |
|
| Overall design |
IMIM-PC1 cells stably expressing the MYC-ER fusion protein were treated with 500nM 4-OHT for an interval of 24h.
|
| |
|
| Contributor(s) |
Wirth M, Biederstädt A, Keller U, Schneider G |
| Citation missing |
Has this study been published? Please login to update or notify GEO. |
| |
| Submission date |
Sep 04, 2018 |
| Last update date |
Mar 27, 2019 |
| Contact name |
Matthias Wirth |
| Organization name |
Charité Berlin
|
| Street address |
Hindenburgdamm 30
|
| City |
Berlin |
| ZIP/Postal code |
12203 |
| Country |
Germany |
| |
|
| Platforms (1) |
| GPL11154 |
Illumina HiSeq 2000 (Homo sapiens) |
|
| Samples (6)
|
|
| Relations |
| BioProject |
PRJNA489233 |
| SRA |
SRP159512 |
Less...
More...